Quinolone derivatives: Potential anti-HIV agent-development and application

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• Acquired immune deficiency syndrome (AIDS)/human immunodeficiency virus (HIV) remains a critical global health challenge.
• The emergence of drug-resistant HIV necessitates the development of novel therapeutic agents.
• Quinolone derivatives are recognized for their potential in vitro and in vivo anti-HIV properties.

Purpose of the Study:

• To review quinolone derivatives with potential anti-HIV activity.
• To analyze structure-activity relationships of these compounds.
• To provide insights for the development of more effective anti-HIV quinolone-based drugs.

Main Methods:

• Comprehensive literature search for articles published between 1992 and 2019.
• Analysis of studies reporting anti-HIV activity of quinolone derivatives.
• Evaluation of structure-activity relationships.

Main Results:

• Numerous quinolone derivatives exhibit promising anti-HIV activity.
• Specific structural features correlate with enhanced efficacy.
• The approved drug elvitegravir is a 4-quinolone, supporting the potential of this scaffold.

Conclusions:

• Quinolone derivatives represent a promising class of compounds for developing new anti-HIV therapies.
• Further research into structure-activity relationships can guide the design of more potent agents.
• Targeted development of quinolone derivatives could address the challenge of drug-resistant HIV.